ArticleArchives of dermatology2012
Chemoprevention for keratinocytic (pre)cancers: balancing the risks and benefits.
Article in Archives of dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
questionCan celecoxib reduce the incidence of actinic keratoses (AKs) and keratinocytic cancers?
designRandomized, double-blind, placebo-controlled phase 2-3 clinical trial.
settingEight centers in the United States participated and included 240 patients from January 2001 to November 2006, when the Food and Drug Administration requested termination of this trial after the worldwide withdrawal of rofecoxib. PATIENTS: The study population comprised individuals 18 years or older with Fitzpatrick skin type I to III, with 10 to 40 AKs on the upper extremities, neck, face, and scalp at baseline and a previous histological diagnosis of a keratinocytic (pre)malignant neoplasm.
interventionCelecoxib (200 mg) or placebo twice daily.
main outcome measureThe ratio of new AKs per patient at completion of the study to the number of AKs at randomization. EXPLORATORY POST HOC ANALYSIS: The mean cumulative number of keratinocytic skin cancers per patient.
resultsThere was no difference in the incidence of AKs between the 2 groups at month 9 after randomization. The adjusted rate ratios for the celecoxib arm compared with the placebo arm were 0.41 (95% CI, 0.23-0.72) for keratinocytic skin cancers, 0.40 (95% CI, 0.18-0.93) for basal cell carcinomas (BCCs), and 0.42 (95% CI, 0.19-0.93) for squamous cell carcinomas (SCCs).
conclusionCelecoxib might be effective for prevention of keratinocytic cancers but not for actinic keratoses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.